[Boston, 4^th June 2025] – The global market for transcatheter (leadless) cardiac pacemakers is projected to grow from USD 1.42 billion in 2024 to USD 3.26 billion by 2031, registering a CAGR of 12.7% according to Clearview Market Insights (CVMI).

“As electrophysiology shifts to minimally invasive solutions, leadless pacemakers are poised to become the new standard of care for bradycardia patients,” said Dr. Alexis Durrant, Cardiac Device Lead at CVMI.

Request Sample @ https://clearviewmarketinsights.com/report-details/global-transcatheter-cardiac-pacemaker-market/

Key Growth Drivers

• Minimally invasive implantation and lower complication rates.
• Aging population with growing demand for pacing support.
• Expansion of approved indications to include AV block.
• Ongoing trials and FDA approvals for dual-chamber systems.

Competitive Snapshot

Medtronic continues to lead with over 70% market share, thanks to its Micra portfolio. Abbott follows with the Aveir VR and the newly CE-marked Aveir DR system. Biotronik and regional OEMs are entering the race with wireless capture and retrieval technology.

Segmentation Overview

By Device Type (2024 Share)

• Single-Chamber – 84 %
• Dual-Chamber – 16 %

By End User (2024 Share)

• Tertiary Cardiac Centers – 52 %
• Academic Hospitals – 26 %
• Private Clinics – 22 %

Single-chamber systems dominate but dual-chamber devices are expected to reach 30 % share by 2030. Private cardiac clinics are projected to grow fastest due to outpatient procedures.

Regional Insights

• North America (45 %) – Medicare covers leadless systems; rapid uptake in outpatient electrophysiology labs.
• Europe (XX %) – Strong CE momentum for dual-chamber pacing.
• Asia-Pacific (XX %) – Japan and China invest in cardiac care modernization.
• LATAM & MEA (XX %) – Pilots in Chile, UAE, and Egypt expand access.

Technology Highlights

• Dual-chamber AV synchronisation.
• Remote Bluetooth monitoring.
• Repositionable and retrievable devices.
• MRI compatibility and miniaturised hardware.
• Clinical validation for younger and active patients.

2031 Market Milestones

• 2026 – Dual-chamber systems gain FDA approval.
• 2027 – Leadless implants become first-line choice for single-chamber pacing.
• 2028 – Battery life exceeds 15 years with new chemistries.
• 2029 – Retrievable pacemakers standardised.
• 2030 – Smartphone-linked telemetry expands globally.
• 2031 – 250,000+ implants/year across 70+ countries.

“We see a global convergence around leadless pacing,” said Dr. Rajiv Sethi, Director of Electrophysiology at St. George’s Hospital London. “Patients benefit from less trauma and quicker recovery, while hospitals reduce long-term complications.”

For more insights, visit https://clearviewmarketinsights.com/report-store  

About Clearview Market Insights

Clearview Market Insights delivers evidence-based strategic analysis across the cardiovascular, rhythm management, and electrophysiology technology landscape.

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369